High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: Association with liver fibrosis and portal inflammation

Human Immunology

Volumn 73, Issue 4, 2012, Pages 382-388

  Sjöwall, Christopher ^a   Cardell, Kristina ^a   Boström, Elisabeth A ^b   Bokarewa, Maria I ^b   Enocsson, Helena ^a   Ekstedt, Mattias ^a   Lindvall, Liselott ^a   Frydén, Aril ^a   Almer, Sven ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Autoantibodies; C reactive protein; Hepatitis C; Interferon ; Resistin

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN AUTOANTIBODY; PROTEIN ANTIBODY; RESISTIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; MALE; MORTALITY; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; AUTOANTIBODIES; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PORTAL SYSTEM; PROGNOSIS; RESISTIN; RETROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES;

EID: 84859029959     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.01.009     Document Type: Article

References (47)

1. Rosen H.R. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011, 364:2429-2438.
2. Kessel A., Toubi E. Chronic HCV-related autoimmunity: a consequence of viral persistence and lymphotropism. Curr Med Chem 2007, 14:547-554.
3. Davis G.L., Lindsay K.L. Treatment of chronic hepatitis C infection: one step at a time. Lancet Infect Dis 2005, 5:524-526.
4. Neal K.R. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007, 56:1098-1104. Trent Hepatitis C Study Group.
5. Schuppan D., Afdhal N.H. Liver cirrhosis. Lancet 2008, 371:838-851.
6. Castera L., Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?. Liver Int 2011, 31(suppl 1):13-17.
7. Lesmana C.R., Salim S., Hasan I., Sulaiman A.S., Gani R.A., Pakasi L.S., et al. Diagnostic accuracy of transient elastography (FibroScan) versus the aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B: the role in primary care setting. J Clin Pathol 2011, 64:916-920.
8. Buskila D. Hepatitis C-associated rheumatic disorders. Rheum Dis Clin North Am 2009, 35:111-123.
9. Palazzi C, Buskila D, D'Angelo S, D'Amico E, Olivieri I. Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev, epub ahead of print 30 November 2011 []. doi:10.1016/j.autrev.2011.11.011.
10. Selmi C., Lleo A., Zuin M., Podda M., Rossaro L., Gershwin M.E. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 2006, 7:451-456.
11. Robey F.A., Jones K.D., Steinberg A.D. C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro. J Exp Med 1985, 161:1344-1356.
12. Shoenfeld Y., Szyper-Kravitz M., Witte T., Doria A., Tsutsumi A., Tatsuya A., et al. Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007, 1108:227-239.
13. O'Neill S.G., Giles I., Lambrianides A., Manson J., D'Cruz D., Schrieber L., et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010, 62:845-854.
14. Wetterö J., Sjöwall C. Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins. Clin Chim Acta 2007, 378:13-23.
15. Sjöwall C., Zickert A., Skogh T., Wetterö J., Gunnarsson I. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther 2009, 11:R188.
16. Kessel A., Elias G., Pavlotzky E., Zuckerman E., Rosner I., Toubi E. Anti-C-reactive protein antibodies in chronic hepatitis C infection: correlation with severity and autoimmunity. Hum Immunol 2007, 68:844-848.
17. Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
18. Sheng C.H., Di J., Jin Y., Zhang Y.C., Wu M., Sun Y., et al. Resistin is expressed in human hepatocytes and induces insulin resistance. Endocrine 2008, 33:135-143.
19. Bertolani C., Sancho-Bru P., Failli P., Bataller R., Aleffi S., DeFranco R., et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006, 169:2042-2053.
20. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
21. Yagmur E., Trautwein C., Gressner A.M., Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006, 101:1244-1252.
22. Petit J.M., Minello A., Brisard C., Galland F., Duvillard L., Verges B., et al. Plasma resistin concentration, and steatosis and insulin sensitivity in hepatitis C virus-infected patients. J Gastroenterol Hepatol 2006, 21:624.
23. Boström E.A., Ekstedt M., Kechagias S., Sjöwall C., Bokarewa M.I., Almer S. Resistin is associated with breach of tolerance and anti-nuclear antibodies in patients with hepatobiliary inflammation. Scand J Immunol 2011, 74:463-470.
24. Tsochatzis E., Papatheodoridis G.V., Hadziyannis E., Georgiou A., Kafiri G., Tiniakos D.G., et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008, 43:1128-1136.
25. Tiftikci A., Atug O., Yilmaz Y., Eren F., Ozdemir F.T., Yapali S., et al. Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. Arch Med Res 2009, 40:294-298.
26. Baranova A., Jarrar M.H., Stepanova M., Johnson A., Rafiq N., Gramlich T., et al. Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C. Digestion 2011, 83:32-40.
27. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
28. Ekstedt M., Franzén L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
29. Batts K.P., Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995, 19:1409-1417.
30. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435.
31. Sjöwall C., Sturm M., Dahle C., Bengtsson A.A., Jönsen A., Sturfelt G., et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. J Rheumatol 2008, 35:1994-2000.
32. Sjöwall C., Bengtsson A.A., Sturfelt G., Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004, 6:R87-R94.
33. Fontana R.J., Dienstag J.L., Bonkovsky H.L., Sterling R.K., Naishadham D., Goodman Z.D., et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010, 59:1401-1409.
34. Mogues T., Li J., Coburn J., Kuter D.J. IgG antibodies against bovine serum albumin in humans-their prevalence and response to exposure to bovine serum albumin. J Immunol Methods 2005, 300:1-11.
35. Sjöwall C., Kastbom A., Almroth G., Wetterö J., Skogh T. Beware of antibodies to dietary proteins in "antigen-specific" immunoassays! Falsely positive anticytokine antibody tests due to reactivity with bovine serum albumin in rheumatoid arthritis (the Swedish TIRA project). J Rheumatol 2011, 38:215-220.
36. Tan Y., Yu F., Qu Z., Su T., Xing G.Q., Wu L.H., et al. Modified C-reactive protein might be a target autoantigen of TINU syndrome. Clin J Am Soc Nephrol 2011, 6:93-100.
37. Wetterö J., Nilsson L., Jonasson L., Sjöwall C. Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta 2009, 400:128-131.
38. Rönnblom L., Alm G.V., Eloranta M.L. The type I interferon system in the development of lupus. Semin Immunol 2011, 23:113-121.
39. Kruse K., Janko C., Urbonaviciute V., Mierke C.T., Winkler T.H., Voll R.E., et al. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis 2010, 15:1098-1113.
40. Sjöwall C., Wetterö J., Bengtsson T., Askendal A., Almroth G., Skogh T., et al. Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction. Biochem Biophys Res Commun 2007, 352:251-258.
41. Mihlan M., Stippa S., Józsi M., Zipfel P.F. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ 2009, 16:1630-1640.
42. Yang X.W., Tan Y., Yu F., Zhao M.H. Interference of antimodified C-reactive protein autoantibodies from lupus nephritis in the biofunctions of modified C-reactive protein. Hum Immunol 2012, 73:156-163.
43. Rees R.F., Gewurz H., Siegel J.N., Coon J., Potempa L.A. Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle. Clin Immunol Immunopathol 1988, 48:95-107.
44. Zuniga R., Markowitz G.S., Arkachaisri T., Imperatore E.A., D'Agati V.D., Salmon J.E. Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune deposits and Fcgamma receptor type IIA alleles. Arthritis Rheum 2003, 48:460-470.
45. Janko C., Franz S., Muñoz L.E., Siebig S., Winkler S., Schett G., et al. CRP/anti-CRP antibodies assembly on the surfaces of cell remnants switches their phagocytic clearance toward inflammation. Front Immunol 2011, 2:70.
46. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
47. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.